Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 9/20 | 0.60 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.60 |
| ▸ | AR | P10275 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504176 | 0.82 | AR (0.60) | SMARCA2SMARCA4AR | |
| SCHEMBL19695438 | 0.82 | AR (0.60) | SMARCA2SMARCA4AR | |
| SCHEMBL19695441 | 0.82 | AR (0.60) | SMARCA2SMARCA4AR | |
| SCHEMBL16303153 | 0.81 | SMARCA2 (0.58) | SMARCA2SMARCA4ARL3MBTL1NPSR1 | |
| SCHEMBL31434913 | 0.81 | SMARCA2 (0.66) | SMARCA2SMARCA4MAPTKDM4EALDH1A1 | |
| SCHEMBL4175713 | 0.81 | SMARCA2 (0.66) | SMARCA2SMARCA4MAPTKDM4EALDH1A1 | |
| SCHEMBL9598470 | 0.81 | SMARCA2 (0.66) | SMARCA2SMARCA4ARKDM4EALDH1A1 | |
| SCHEMBL1501665 | 0.81 | SMARCA2 (0.57) | SMARCA2SMARCA4AR | |
| SCHEMBL9599834 | 0.80 | SMARCA2 (0.86) | SMARCA2SMARCA4MAPTALDH1A1 | |
| SCHEMBL13015661 | 0.80 | PRKCI (0.59) | SMARCA2SMARCA4ARL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-06-05 | — | — | US | disclosed |
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-06-05 | — | — | US | disclosed |
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-06-05 | — | — | US | disclosed |
| EP-1838152-A2 | IMIDAZOLYLMETHYL AND PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006078891-A2 | IMIDAZOLYLMETHYL AND PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078891-A2 | IMIDAZOLYLMETHYL AND PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20030004165-A1 | Polyazanaphthalene compounds and pharmaceutical use thereof | AJINOMOTO CO. INC (JP) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132510-A1 | Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives | GABRR3, GABRA3, GABRR1 | SMARCA2 3110/4885SMARCA4 3386/4885AR 680/4885 |
| US-20110201610-A1 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | SMARCA2 1512/4885SMARCA4 1704/4885AR 1055/4885 |
| US-20030004165-A1 | Polyazanaphthalene compounds and pharmaceutical use thereof | MMP1, TNF, MMP12 | SMARCA2 3099/4885SMARCA4 2803/4885AR 1694/4885 |
| US-20120101097-A9 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | SMARCA2 1512/4885SMARCA4 1704/4885AR 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.